As the market’s leading independent healthcare equity research provider, we strive to separate market noise from the insights that are essential to the investment process.
Nephron’s primary differentiators lie in our research teams and their approach to equity research. The deep experience and insight of our analysts as well as an intense drive to serve a discerning client base sets us apart. With the sole focus of creating value for clients, Nephron can provide a depth of coverage, breadth of access, and consultative services that traditional models lack.
Delivered via an independent and unbiased subscription-only model, Nephron is directly aligned with our client’s interests and investment processesMeet The Team
At Nephron Research, our experience and connectivity drive deep research products which is supplemented by hyper-relevant corporate access
We tackle the most important debates, react quickly, and provide leading perspective
NEPHRON RESEARCH COVID-19 Daily Tracker: June 3, 2020; Hot Spots - StatesDownload
HMOs and Hospitals: 20 Questions and 20 Answers to Quantify the COVID19 ImpactDownload
A Closer Look: COVID-19 Script Declines Represent an Acute, Not Chronic, ProblemDownload
Nephron Research Curates Dozens of Events Each Year Designed for Maximum Impact to Client Investment Process
Preparing for Humira + New and Disruptive Models. Confirmed Participants: Cigna/Evernorth, Prime Therapeutics, Evio + BCBS of Michigan, Emsana + The Purchaser Business Group on Health, Capital Rx, EQRx, Vizient, Mercer Health & Benefits, and many more…
The second annual LBx Symposium where Jack Meehan will host both public and private companies alongside experts in the field.
A joint-call between our Health Policy and Healthcare Services teams looking at one of our most followed topics – value based care. Discussion on ACO REACH & other Medicare value based programs, MA, and physician enablement. Amy Bassano from Health Management Associates, and Kelsey Stevens from Wakely Consulting.
Our independent model and deep healthcare and investment expertise allows us to deliver a full suite of bespoke
and consultative services to investment firms and market participants.
The 2022 Benefit Innovation Symposium will center on three key topics:
Preparing for Humira: We will examine PBM, Payor and Employer biosimilar strategies for 2023 and beyond.
Rebate Contracting Entities: A deep dive into Cigna’s Ascent and Prime’s emergence as the aggregator of aggregators.
New & Disruptive Models: Our picks for potential disruption: ‘New Payor’ (Evio), ‘New PBM’ (Emsana, Mark Cuban Cost Plus Drug Company, & CapitalRx), ‘New Pharma’ (EQRx & Biosim Mfrs.), and many more…